DE-QPS-HOLDINGS
QPS, a leading global contract research organization (CRO), continues to expand and align its full-service preclinical, bioanalysis, and clinical capabilities with the evolution of demand for clinical trials. Today, QPS announced the expansion of its Miami, Florida Phase I clinical trial capabilities to support the growing needs of sponsors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240521634782/en/
New, state of the art, clinical trial unit at QPS Miami in South Miami, Florida USA. (Photo: Business Wire)
QPS announces the grand opening of its newest clinical trials unit in Miami, Florida. This new 21 bed unit will complement the existing 85 bed clinical trials unit currently serving the Biotech and Pharmaceutical community. With this new capacity, QPS is poised to accommodate the rapidly increasing demand for obesity trials, as well as continue to support complex, early phase studies in special populations. QPS has extensive experience in allergies, asthma, cell & gene therapy, CNS, COPD, diabetes, elderly, oncology, pediatrics, rheumatoid arthritis, vaccines, women’s health, and many more therapeutic areas.
“We have expanded our Phase I clinical trial capabilities to better serve the hundreds of companies developing potential new obesity-related drugs. We have completed more than 1,500 Phase I-IV clinical trials for drug candidates and this expansion will enable us to support exponentially more sponsors as they progress compounds through proof of concept and First-in-Human trials to the point of candidate nomination,” said Benjamin Chien, Chairman, President, and CEO, QPS Holdings, LLC.
“Our pipeline is filled with sponsors that need this level of support. The number of First-in-Human studies is rapidly increasing and there are very few sites across the country that can conduct them,” said Jose Marcos, Vice President of Clinical Operations, QPS Miami. “QPS is well-known for its success in First-in-Human studies. We excel at complex and special population Phase I trials, and our enrollment and completion rates are among the best in the industry.”
With the expansion comes an increased focus on quality. “To ensure the quality of our clinical trials is maintained, QPS has hired an additional full-time principal investigator to ensure dedicated, physician-involvement at every stage of our trials,” said Chien. “We now have five full-time principal investigators, and a network of more than 25 board-certified subspecialty physician investigators to support the increased volume of studies in our pipeline.”
Wendy Marquina, MD, American Board of Obesity Medicine certified physician, has joined QPS as a primary investigator dedicated to Phase I trials. She brings Board Certification in Obesity, as well as expertise in internal medicine and women’s health to QPS. Since the discovery of the anti-obesity effects of GLP1 and GIP inhibitors, the number of obesity-related clinical trials has dramatically increased. More than 2,300 clinical studies related to obesity are listed as ongoing on clinical trials.gov, and the number is increasing as more companies join the effort to tackle this serious disease and its related comorbidities.
“We expect this demand for obesity-related studies to continue,” said Marquina. “Obesity trials are specialized and unique. And they are in high demand, particularly for companies that want to find an effective solution to this debilitating disease. The road so far is littered with failures in this space, so there is real excitement in the medical community that there may finally be a pathway to help these patients.”
Supporting this expansion in Miami, QPS has co-located its specialty lab services within its Miami-based clinical site. “In the market, you’ll find CROs that offer clinical services, and then you’ll find specialized labs. At QPS, we now we have the unique combination of clinical services and a specialized lab combined under one roof,” said Chien. “That’s important because many of our studies require lab samples to be processed quickly, in less than eight hours. This is only possible by having the clinical site and specialty lab co-located.”
With this newly expanded facility and additional leadership specializing in obesity, QPS is satisfying the need for agility, flexibility, and speed in the global drug development community, with a focus on serving the needs of the Biotech and Pharmaceutical industry to support global drug development from preclinical through post-marketing needs.
ABOUT QPS HOLDINGS, LLC
QPS is a GLP- and GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, preclinical, and clinical drug development services. Since 1995, it has grown from a tiny bioanalysis shop to a full-service CRO with 1,200+ employees in the US, Europe and Asia. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, clinical trials and clinical research operations services. An award-winning leader focused on bioanalytics and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, and turnkey laboratories and facilities. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance and trusted service to its valued customers. For more information, visit www.qps.com or email infopr@qps.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521634782/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tholos Foundation Reveals Critical Risks of Proposed Nicotine Pouch Regulations4.12.2024 22:01:00 CET | Press release
The Tholos Foundation, in collaboration with IPSOS & HBS Economics, today released groundbreaking research exposing the risks of the proposed Danish regulations limiting nicotine content in nicotine pouches to 9 mg per pouch. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241204248551/en/ Key findings highlight significant public health and economic concerns The comprehensive study reveals alarming potential outcomes if the proposed nicotine limit is implemented: Consumer behavior shifts Half (50%) of current nicotine pouch users would seek alternative purchasing channels, either online or across the border of other EU countries One in five (18%) users might return to smoking Proposed limit threatens Denmark's remarkable progress in reducing smoking rates from 19% to 14% between 2018 and 2023** Public health implications 3 out of 4 (75%) users originally chose nicotine pouches for health-related reasons, primarily to reduce
Andersen Global udvider sin dækning af Filippinerne med Gravitas Prime4.12.2024 21:46:00 CET | Pressemeddelelse
Andersen Global indleder yderligere ekspansion i Asien og Stillehavsområdet gennem en samarbejdsaftale med Gravitas Prime, der arbejder med fusioner og overtagelser i Filippinerne. Gravitas Prime blev grundlagt i 2005 af daværende bestyrelsesformand Ed David, og tilbyder en omfattende pakke af tjenester, herunder fusioner og overtagelser, virksomhedsstrategi, værdiansættelse af virksomheder, ejendomsplanlægning og kapitalrejsning. Firmaet driver strategiske initiativer for et forskelligartet kundegrundlag. Det råder over specialiseret ekspertise inden for forbruger, detailhandel, mad og drikkevarer, QSR, lægemidler og sundhedspleje, hotel-, restaurations- og oplevelsesbranchen, energi og vedvarende energikilder. Gravitas Prime har opbygget stærke relationer med en bred vifte af strategiske investorer, herunder familiekontorer, førende selskabskonglomerater og private equity-selskaber. "Her i firmaet har vi altid fokuseret på værdiforøgelse, på at drive vækst og identificere muligheder
Almirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and Healthcare4.12.2024 16:58:00 CET | Press release
80th anniversary commemorative eventsThe Hive is aimed at advancing research in life sciences by a novel approach to collaboration - creating an open innovation hub designed to build close relationships between biotech companies, start-ups, academics, and Almirall scientistsThe network will be enlarged with the arrival of Admit Therapeutics and Microomics, in addition to the current members of the hub ZeClinics and Centrient PharmaceuticalsThis novel approach to pushing the boundaries of science and innovation in the year of Almirall’s 80th anniversary is part of the company’ s innovation strategy, long-term vision, commitment to patients, and the advancement of healthcare Almirall, a global pharmaceutical company dedicated to medical dermatology, today announced the launch of “The Hive”, a novel scientific research hub located at its R&D centre in Barcelona, Spain. The Hive is designed to foster collaboration among researchers from biotech companies, start-ups, academia, and Almirall’
Now Is the Time To Host Events in Japan, With the Yen at a Low! Global Produce Launches Full-Scale Production of “Event Hosting in Japan” for Overseas Companies4.12.2024 16:00:00 CET | Press release
Providing English support, potential venues such as arenas and historic buildings, and more—a team of event professionals bringing unique, extraordinary, and emotional events to life! Global Produce Co., Ltd. (Head Office: Shibuya Ward, Tokyo; CEO: Masaki Kouhata; hereinafter referred to as “Global Produce”), a company specializing in event production, is pleased to announce the full-scale launch of its production services for overseas companies looking to host events in Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121186571/en/ Global Produce Launches Full-Scale Production of “Event Hosting in Japan” for Overseas Companies (Graphic: Business Wire) With Global Produce, your dream event in Japan can become a reality! Our “Japan Event Hosting Plan” was created to bring the visions of overseas companies to life using events hosted in Japan. Not only will native speakers be present at the forefront, but our producers
DataXstream Launches OMS+ Cloud for SAP S/4HANA Cloud Public Edition4.12.2024 15:03:00 CET | Press release
The newest product offering delivers B2B point of sales and order management capabilities to SAP Public Cloud Users Worldwide DataXstream LLC, an SAP® Endorsed app and Gold-level partner developing innovative solutions for SAP sales and distribution, today introduced OMS+ Cloud for SAP S/4HANA Cloud Public Edition. OMS+ has streamlined complex sales and order processes for SAP users for over a decade within SAP ECC and S/4HANA Cloud Private Edition environments. But recent forecast numbers from Gartner show that worldwide spending on public cloud services is increasing significantly and will reach a total of $723.4 billion in 2025, with a 19% growth increase in Cloud Application Services (SaaS). (Source: Gartner, November 2024) DataXstream’s OMS+ Cloud will now extend its award-winning OMS+ platform by delivering end-to-end point of sales (POS) and order management capabilities for SAP Public Cloud. OMS+ Cloud will simplify complex POS, quote and order processes often associated with v
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom